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Abstract  
Background: Much is written about the promise of telehealth and there is great enthusiasm 
about its potential. However, many studies of telehealth do not meet orthodox quality 
standards and there are few studies examining quality of life in diabetes as an outcome. 
Objective: To assess the impact of home-based telehealth (remote monitoring of 
physiological, symptom and self-care behavior data for long-term conditions) on generic and 
disease-specific health-related quality of life, anxiety, and depressive symptoms over 12 
months in patients with diabetes. Remote monitoring provides the potential to improve 
quality of life, through the reassurance it provides patients. 
Methods: The study focused on participant-reported outcomes of patients with diabetes 
within the Whole Systems Demonstrator (WSD) Telehealth Questionnaire 
Study, nested within a pragmatic cluster-randomized trial of telehealth (the WSD Telehealth 
Trial), held across 3 regions of England. Telehealth was compared with usual-care, with 
general practice as the unit of randomization. Participant-reported outcome measures (Short-
Form 12, EuroQual-5D, Diabetes Health Profile scales, Brief State-Trait Anxiety 
Inventory, and Centre for Epidemiological Studies Depression Scale) were collected at 
baseline, short-term (4 months) and long-term (12months) follow-ups. Intention-to-treat 
analyses testing treatment effectiveness, were conducted using multilevel models controlling 
for practice clustering and a range of covariates. Analyses assumed participants received their 
allocated treatment and were conducted for participants who completed the baseline plus at 
least one follow-up assessment (n=317).  
Results: Primary analyses showed differences between telehealth and usual care were small 
and only reached significance for 1 scale [dibetes health profile-disinhibited eating, P=.006). 
The magnitude of differences between trial arms did not reach the trial-defined minimal 
clinically important difference of 0.3 standard deviations for any outcome. Effect sizes 
(Hedge's g) ranged from 0.015 to 0.143 for Generic quality of life (QoL) measures and 0.018 
to 0.394 for disease specific measures.  
Conclusions: Second generation home-based telehealth as implemented in the WSD 
evaluation was not effective in the subsample of people with diabetes. Overall, telehealth did 
not improve or have a deleterious effect quality of life or psychological outcomes for patients 
with diabetes over a 12-month period. 
Introduction 
The increasing demands of diabetes care on health resources in many countries [1] has led to 
the development of innovative information-communication-technology–based interventions 
that facilitate patient self-care and the monitoring and communication of disease status to 
health care professionals [2]. The range of technologies includes disc- and computer-based 
systems [3], Web-based interventions [4,5], mobile apps [6], remote monitoring systems 
[7,8], and combinations of these.  One system gaining traction in the last 10 years is 
telehealth, which involves the remote exchange of physiological or symptom data between a 
patient and health care professional [9,10]. Algorithms within systems logging the data sent 
can alert health care professionals when disease-specific clinical parameters are breached; 
allowing the potential for earlier intervention, which can reduce the frequency with which 
expensive hospital-based care is required, and thereby improving patient outcomes (eg, 
reducing avoidable hospitalizations, improving clinical parameters) and health-related quality 
of life (HRQoL), the latter of which is the focus of this paper. 
Primary studies and systematic reviews that have examined the effect of telehealth on 
HRQoL in people with diabetes, typically conclude that telehealth leads to QoL 
improvements, potentially because of improved care processes and health status, and 
reductions in worry about timely interventions as physiological and physical status are being 
monitored by health care professionals. For example, one potential pathway by which 
telehealth impacts patient outcomes is the increased feelings of reassurance participants get 
by being more closely monitored by the health care team, the other potential mediating 
mechanism it that increasing knowledge of the condition and increasing confidence leads to 
improvements in self-care behaviors, such as checking feet regularly, and so on [11]. 
However, in 1 systematic review [12], it was not possible to quantitatively synthesize the 
evidence on patient outcomes due to the heterogeneity of the patient-reported outcomes 
(PROMS). The authors found 5 studies that measured HRQoL, and of these 4 reported no 
significant differences [13-16], which is consistent with a recent randomized controlled trial 
(RCT) that found no differences in PROMs in a UK-based telehealth service [7]. In contrast, 
Chumbler et al. [17] found statistically significant improvements in 3 of 8 short-form (SF-36) 
subscales (role functioning, bodily pain, and social functioning) after 1 year of home 
telehealth. A further source of heterogeneity in the studies is the mixture of generic versus 
disease specific measures of HRQoL.  
Few studies, however, have examined psychological distress. This is despite some contention 
about whether telehealth, despite monitoring benefits, can have potentially detrimental effects 
increasing patient burden and distress [18], through greater isolation and reduced face-to-face 
contact with health care professionals [19], and at times low acceptability of telehealth [20]. 
The evidence base for telehealth in people with diabetes is characterized by methodologically 
weak studies that generate equivocal findings and the studies have been critiqued for their 
variability in quality (small samples, poor methodology, few RCTs) and heterogeneity (in 
systems examined and outcomes measured) that has made the information produced difficult 
to interpret or synthesize [12]. The effectiveness of telehealth, in terms of QoL benefits, has 
yet to be substantiated in high-quality trials. Furthermore, few studies have used diabetes-
specific QoL instruments, which are more sensitive to changes in this population than generic 
QoL measures, and few studies have extended the psychosocial outcomes to examine anxiety 
and depression.  
The current study was part of the Whole Systems Demonstrator (WSD) programme, 
commissioned by the UK Department of Health. A previous paper has already reported on 
the effect of telehealth on HbA1c control in the larger diabetes trial cohort [21]. This paper 
reports on a subsample of the cohort providing data on the PROMs. It aimed to address the 
inconsistencies in data observed in previous research in telehealth and patient-reported QoL 
outcomes, and evaluated the effectiveness of telehealth in a sample of people with diabetes, 
examining its effect on HRQoL and psychological distress in the short and long term. It was 
hypothesized that should telehealth demonstrate significant improvements in QoL measures, 
these would be detected in disease-specific measures to a greater degree than generic QoL 
measures; and that telehealth would significantly improve psychological distress due to the 
reassurance the monitoring systems would provide to patients. 
Methods 
Design and Randomization 
The WSD evaluation was one of the largest trials evaluating telehealth and telecare in the 
United Kingdom. The detailed protocol and design for the WSD evaluation has been reported 
elsewhere [22]. Within the evaluation, the WSD Telehealth Trial (n=3230) was a multicenter, 
pragmatic, cluster-RCT of telehealth across 3 regions in England (Cornwall, Kent, and the 
London Borough of Newham) with a nested questionnaire study, the WSD Telehealth 
Questionnaire Study (1573/3230, 48.7%).  
Participants in the trial were allocated to a trial arm (ie, telehealth or usual care) using cluster 
randomization, based on participants’ registration with a general practice. Allocation was 
balanced for region (WSD site), practice size, deprivation index, non-white proportion and 
prevalence of diabetes, chronic obstructive pulmonary disease, and congestive heart failure, 
using an algorithm by the trial statistician. For individual participants, trial arm allocation 
was maintained from the main trial, through to the questionnaire study and diabetes 
participant analyses. The WSD Telehealth Questionnaire Study involved a total of 204 
general practices recruited across the 3 WSD Sites, of which 111 contributed participants to 
the diabetes questionnaire analysis; 46.8% (52/111) in the control and 53.2% (59/111) in the 
intervention trial arm.  
Participants diagnosed with diabetes were recruited between May 2008 and December 2009 
from 4 primary care trusts across the 3 WSD regions. Final 12-month follow-ups were 
conducted in December 2010.  Participants in the trial were invited to take part in a nested 
questionnaire study measuring PROM. Neither participants nor assessors could be blinded to 
trial arm allocation, due to the nature of the intervention. Participants not allocated to receive 
telehealth were informed that they would be offered the technology at the end of the trial 
period, following a reassessment of need.  
The study protocol was approved by the Liverpool Research Ethics Committee (Reference 
number: 08/H1005/4). Full consent procedures are available in the protocol papers by Bower 
et al. [22] and Cartwright et al. [8]. In brief, practices at each of the sites signed 
memorandums of agreement to participate in the trial. Telehealth trial participants provided 
signed, informed consent to share data with the trial team; with those going onto the 
questionnaire study, providing further signed consent. 
Participants 
Adult patients at participating general practices were deemed eligible for the study if they 
were diagnosed with diabetes according to: (1) the Quality Outcomes Framework register in 
primary care, (2) a confirmed diagnosis in medical records as indicated by general practice 
Read Codes or the International Statistical Classification of Diseases and Related Health 
Problems-10 codes, or (3) confirmation of diabetes by a clinician involved in their care. 
Participants were not excluded because of additional co-morbidities. However, they were 
required to have sufficient cognitive capacity and English language skills to complete a self-
reported questionnaire and use telehealth kit.  
Participants were also required to have a landline telephone for broadband Internet 
connection, and in the London Borough of Newham an additional requirement was a 
television set. Local WSD project teams paid for financial costs associated with the telehealth 
(including phone calls to the monitoring centers, broadband service, and data transmission to 
the monitoring centers). 
Telehealth Treatment: Intervention Arm 
 WSD sites delivered variations of a ‘second generation’ telehealth [23] that had a focus on 
monitoring vital signs, symptoms, and self-management behaviors, and providing health 
education in common. A full description of the intervention is published elsewhere [8]. 
In general, participants with diabetes in the trial arm received a glucometer and blood 
pressure monitor, plus additional peripherals depending on clinical need (eg, weighing scales, 
pulse oximeter, peak-flow meter, thermometer).  The peripheral devices were attached to a 
home monitoring system comprising a base unit with a liquid-crystal display screen to allow 
questions about health and educational messages to be transmitted to participants or set-top 
box that connected to a television allowing symptom questions, educational videos, and a 
graphic history of clinical readings to be accessed via a dedicated channel.  Participants were 
asked to take measurements via the peripherals on a schedule determined via individual 
circumstances (eg, daily readings, twice weekly readings). 
Data transmitted by participants to a monitoring center were processed via an algorithm for 
unusual patterns, out of range values, and/or missing data. Contravening a rule triggered an 
alert to an operator at a monitoring center who would follow a decision tree to determine an 
appropriate response. The range of responses included: doing nothing – wait and see 
approach; requesting a repeat reading through the telehealth kit, contacting the participant or 
their named informal carer, arranging a visit to the participant’s home by their community 
matron, or referring to another health care service, as appropriate. The intervention arm 
participants received the telehealth in addition to usual health and social care.  At the end of 
the 12-month trial participants were given the option of keeping telehealth or having it 
removed from their home.  
Usual-Care Treatment: Control Arm 
Participants randomized to the control arm received usual health and social care in line with 
local protocols for the 12-month duration of the trial (eg, combination of community matrons, 
district nurses, specialist nurses, general practice, and hospital services based on clinical 
need). At the end of the trial control participants were offered the installation of telehealth 
services in their homes, if they were still eligible following a needs assessment. 
Trial Assessment Procedures 
Outcome measures were self-completed by participants. At baseline, a trained researcher was 
on hand to explain or clarify the meaning of particular questions or assist with the completion 
of the questionnaire. Two further assessments were conducted at short-term follow-up 
conducted at approximately 4 months (median duration = 128 days; interquartile range [IQR] 
= 47 days) and a long-term assessment, conducted at approximately 12-months (median 
duration = 366 days; IQR = 54 days).  
The short-term follow-up questionnaire was primarily administered as a postal survey with 1 
reminder letter for nonresponders; some participants also received telephone reminders. 
Long-term follow-up surveys were posted to participants, with nonresponders contacted to 
arrange home interviews with a trained researcher in line with the baseline protocol. 
Participants who withdrew from the trial, including intervention participants who asked for 
the telehealth equipment to be removed before the end of the trial period, were not sent 
further questionnaires.    
Outcome Measures  
Generic and disease-specific HRQoL was assessed by: (1) the SF-12  [24] subscales for 
physical component summary (PCS), and mental component summary (MCS), (2) EuroQual 
(EQ-5D) York-Tariff [25], 1990, which produces a summary index over 5 domains (mobility, 
self-care, usual activities, pain/discomfort, and anxiety/depression), (3) the diabetes health 
profile (DHP) [26] with subscales measuring psychological distress, barriers to activity and 
disinhibited eating, and (4) study-specific diabetes HRQoL measures of social 
marginalization and social conspicuousness. Measures were also taken of anxiety with the 
brief state trait anxiety inventory (STAI) [27] and depressive symptoms by the 10-item 
Center for Epidemiologic Studies Depression scale (CESD-10) [28]. Higher scores on the 
QoL instruments pertained to better QoL and higher scores on the anxiety and depression 
instruments indicated greater psychological distress.  
Demographic information recorded included age, sex, ethnicity, number of co-morbid 
conditions, and level of education. Participants’ levels of deprivation were allocated using an 
Index of Multiple Deprivation score [29] as assessed through postcodes.  
Sample Size Calculation  
For the disease-specific aspects of the questionnaire study, a power calculation was 
conducted on the basis of detecting a small effect size, equivalent to a Cohen d of 0.3 [30], 
allowing for an intracluster correlation coefficient of 0.05, power of 80% and P<.05. This 
indicated that between 420 and 520 participants would be required to allow sufficient power 
to detect this small difference taking account of the cluster design. These numbers were 
inflated by 10% to allow for the maximum possible increase in sample size due to variable 
cluster size. The required minimum sample size increased to 550. 
Statistical Methods 
Missing data rates (at the scale/item level used in analyses) among those returning 
questionnaires at short and long term were low (≤3%) and were imputed (m=10) using the 
SPSS MCMC function within each administration. Thereafter, standard multiple imputation 
procedures were employed [31]. Details of multiple-imputation processes are available from 
the authors. 
Sample Characteristics 
Frequencies and mean scores are reported for each trial arm at each follow-up. Analyses were 
conducted on a modified intention-to-treat basis (ie, available case analyses – where data was 
available for baseline plus at least 1 follow-up point). 
Detecting Telehealth Effects 
Repeated measures in each outcome over the 1-year follow-up period were analyzed with 
linear mixed-effects modeling procedures to detect: trial-arm effects, time effects, and their 
interaction. This method took account of the hierarchy within the data observations (ie, 
assessment points, were nested within participants, nested within general practices). Data are 
presented as estimated marginal means (EMMs) with standard errors (SE). 
Covariates to adjust for case-mix differences between trial arms were: age, sex, deprivation, 
ethnicity, co-morbidities, highest education level, WSD site, number of devices, and baseline 
outcome score. For all parameter tests the alpha level was set to .05; Sidak’s adjustment was 
used to compensate for post hoc multiple comparisons; 95% confidence intervals (CI) were 
used to account for the uncertainty in the estimates. Effect sizes for the trial arm effects of 
each outcome were reported as Hedge’s g. Analyses were conducted in SPSS v19. 
Results  
Sample Recruitment and Attrition 
Of the 3230 participants in the WSD Telehealth Trial, 23.6% (763/3230) were indexed as 
participants with diabetes. Of the 1573 participants in the nested telehealth questionnaire 
study, 28.9% (455/1573) were people with diabetes; of these 54.1% (246/455) were in the 
intervention arm and 45.9% (209/455) were in the usual care arm. Figure 1 shows 
participants per trial arm within the questionnaire study.  
Sample Characteristics  
Baseline sample characteristics by trial arm of the 455 questionnaire participants are reported 
in Table 1. The mean age of the sample was approximately 65 years with most participants 
being of white, British/Irish ethnicity. Most participants came from the London Borough of 
Newham WSD Site, and were mainly male. The sample had on average 2 co-morbid 
conditions and the majority (247/455, 54.3%) had received little formal education. On 
average, the intervention group received just short of 3 telehealth devices. In the telehealth 
arm 237 glucometers were distributed, with 232 blood pressure monitors, 185 weight scales, 
and 56 pulse oximeters. 
Table 1. Baseline sample characteristics per trial arm of questionnaire participants with 
diabetes. 
 Intervention Control Total 
 
n=246  
(54.1%)  
n=209 
(45.9%)  
N=455 (100%) 
  
Site
a
  
Cornwall 64 (26.0) 55 (26.3) 119 (26.2) 
Kent 44 (17.9) 46 (22.0) 90 (19.8) 
London Borough of 
Newham 
138 (56.1) 108 (51.7) 246 (54.1) 
Sex
a
  
Female 115 (46.7) 84 (40.2) 199 (43.7) 
Male 131 (53.3) 125 (59.8) 256 (56.3) 
Ethnicity  
Non-white 79 (32.1) 72 (34.4) 151 (33.2) 
White British / Irish 167 (67.9) 137 (65.6) 304 (66.8) 
    
 Mean (standard 
error) 
Mean (standard 
error) 
Mean (standard 
error) 
Age, years
a
 64.72 (.874) 65.27 (.875) 64.97 (.620) 
Deprivation score 35.12 (.957) 33.70 (.896) 34.47 (.661) 
Number of 
Comorbidities
a
 
2.11 (.118) 2.17 (.128) 2.14 (.087) 
Amount of telehealth – 
number of devices
a
 
2.89 (.047) 0.16 (.051) 1.64 (.073) 
Level of education 0.83 (.078) 0.97 (.088) 0.89 (.059) 
SF-12
b
 Physical 
Component Scale  
30.31 (0.61)  30.75 (0.66) 30.51 (0.45) 
SF-12
 
Mental 
Component Scale 
35.27 (0.57) 35.38 (0.61) 35.32 (0.42) 
EQ5D
c
 scale  0.50 (0.02) 0.52 (0.03) 0.51 (0.02) 
State Anxiety scale 
(Brief STAI
d
) 
11.37 (0.29) 10.92 (0.31) 11.16 (0.21) 
Depression scale 
(CESD10
e
) 
11.10 (0.44) 10.32 (0.45) 10.74 (0.32) 
Disinhibited eating 
DHP
f
-subscale  
42.44 (1.28) 41.39 (1.24) 41.96 (0.90) 
Psychological Distress 
DHP-subscale  
23.84 (1.54) 24.03 (1.66) 23.93 (1.12) 
Barriers to activity 
DHP-subscale  
32.58 (1.44) 32.81 (1.65) 32.69 (1.08) 
Social Impact DHP-
subscale  
12.20 (1.03) 11.79 (1.04) 12.01 (0.73) 
Social marginalization 
DHP-subscale  
13.61 (1.09) 13.64 (1.13) 13.62 (0.79) 
Social 
conspicuousness DHP-
subscale  
10.30 (1.21) 9.22 (1.17) 9.81 (0.84) 
 
a
Not multiply imputed. 
b
Short-Form 12 item survey. 
c
EuroQol
 
d
State Trait Anxiety Inventory. 
e
Center for Epidemiologic Studies Depression scale 
f
Diabetes Health Profile.
 
Unadjusted means by trial arm for baseline PROM data are presented in Table 1. CIs 
calculated around each mean suggested differences between the telehealth and usual care 
groups were not statistically significant in any measure at baseline.  
Physical and mental health component scores for the SF12 and EQ5D health status measures 
were lower/equal than population averages, but were considered appropriate for a population 
in this age range with long-term conditions [24,25]. Both anxiety and depression levels were 
slightly high with the depression level means close to the cut-off point for screening clinical 
levels of depression. The diabetes health profile (DHP) scales and additional social-based 
HRQoL scales (social conspicuousness and social marginalization) did not indicate problems 
with diabetes specific QoL, and showed a relatively well-functioning long-term condition 
sample. 
Detecting Telehealth Effects 
Table 2 presents key parameter estimates for the effect of trial arm, time, and their interaction 
from linear mixed-effects modeling analyses (adjusting for case-mix) conducted for each 
outcome (parameters for covariates are not presented). Only 1 effect from the 10 PROMs was 
significant, on the DHP disinhibited eating subscale – where a significant trial arm effect was 
detected. Adjusted means (EMMs) for each outcome measure by trial arm and time point are 
presented in Figure 2, (for unadjusted means see Multimedia Appendix 1). 
Table 2. Parameter estimates for trial arm and time in the linear mixed-effects modeling 
analysis for available cases (n=317). 
  Trial Arm Time Time × Trial Arm  
  Estima
te 
Standa
rd 
error 
Signifi
cance 
Estima
te 
Standa
rd 
error 
Signifi
cance 
Estima
te 
Standa
rd 
error 
Signific
ance 
          
SF 12 - PCS
a 
0.338 1.801 0.851 0.335 0.703 0.634 −0.298 0.976 0.760 
SF 12 – MCSb 1.806 1.776 0.309 −0.024 0.639 0.970 0.024 0.881 0.978 
EQ5D
c
 0.087 0.068 0.201 0.021 0.026 0.417 −0.050 0.036 0.167 
Anxiety −0.232 1.053 0.825 0.604 0.415 0.146 −0.250 0.568 0.660 
Depression 0.488 1.364 0.720 0.100 0.528 0.849 −0.189 0.734 0.797 
Psychological 
Distress 
−1.161 4.63 0.802 0.042 1.826 0.982 3.491 2.64 0.187 
Barriers to activity  3.561 4.524 0.431 1.779 1.694 0.294 −1.293 2.441 0.596 
Disinhibited eating 10.674
d
 
3.847
d
 0.006
d
 1.754 1.649 0.287 −0.649 2.386 0.786 
Social 
marginalization  
−3.476 3.677 0.345 −0.703 1.493 0.638 2.288 2.087 0.273 
Social 
conspicuousness 
−2.275 3.374 0.500 0.764 1.427 0.592 1.610 1.973 0.415 
 
a
Short Form 12-item Physical Component Summary. 
b
Short Form 12-item Mental Component Summary. 
d
Significant effects (P<.05). 
Parameter estimates indicate that being a member of the telehealth intervention trial arm 
provides an approximately 10-point advantage on the DHP disinhibited eating scale (after the 
intracluster correlation, all covariates and data hierarchy are taken into account), as indicated 
by EMM of the DHP disinhibited eating scale of the control (mean=35.512, SE=2.074) and 
intervention arms (mean=45.861, SE=2.086; F1,757.625=7.697, P=.006). Effect-size estimates 
reveal this to be a small to medium effect, however the effect size had large 95% CIs, which 
crossed the 0 border (Figure 3). 
The only measure to have ES CI that did not cross the 0 mark was the EQ-5D. However, the 
estimated effect size was very small (Cohen criteria) and the upper CI did not exceed 0.2, 
suggesting that although this is a robust ES, its magnitude is unlikely to have a substantial 
clinical impact. 
Sensitivity analyses (ie, analyses per protocol, with complete cases, and/or excluding 
covariates) indicated similar trends in effects.  
Discussion 
Principal Findings 
This analysis examined the effect of telehealth on participant reported outcomes in a 
relatively large sample of patients with diabetes, who partook in the WSD telehealth trial.  
Overall scores for the sample indicate that physical and mental health component scores for 
the SF12 and EQ5D health status measures were similar to a population with diabetes. Both 
anxiety and depression levels were slightly high, with the depression level means close to the 
cut-off point for screening clinical levels of depression. The DHP scales and additional 
social-based HRQoL scales (social conspicuousness and social marginalization) did not 
indicate problems with diabetes-specific QoL, and indicated a relatively well-functioning 
long-term condition diabetes sample. 
The telehealth group means generally indicated marginally better generic HRQoL outcomes 
for the telehealth group; and the usual care better marginally better outcomes on the disease-
specific and psychological distress scales. However, overall these differences did not reach 
statistical significance, with the results suggesting that telehealth, relative to usual care, does 
not significantly impact upon patients HRQoL (generic and disease-specific) or their 
psychological distress over a period of 12 months. Nor does the status of these participants’ 
PROMs greatly alter over the 12-month period, regardless of their treatment group. 
The only significant effect across the analyses of the PROMs was found on the DHP 
disinhibited eating subscale – where a significant trial arm effect was detected. Parameter 
estimates indicated that being a member of the telehealth intervention trial arm provided an 
approximately 10-point increase on the DHP disinhibited eating scores. This may have 
indicated that with telehealth patients are more likely to undertake disinhibited eating (eg, 
lack eating control, emotional eating), perhaps as a response to knowing that should any 
effects of lacking eating control become extreme, they are being monitored and health care 
professionals will be able to suitably intervene. The provision of telehealth has the potential 
to increase individual’s empowerment and self-care behaviors to manage their conditions 
through remote monitoring, rather than leading to a reliance of health care professional 
control. The mechanisms of such unexpected negative effects need further investigation in 
relation to theoretical constructs of behavioral change. Furthermore, effect-size estimates 
revealed this effect on disinhibited eating to be a small to medium effect, with large CIs that 
crossed the 0 border, indicating poor reliability in this estimate.  
The only outcome with an effect size CI that appeared robust was with the EQ5D measure. 
However, the magnitude of this effect indicated that it would unlikely be clinically 
significant. The lack of effects on these PROM could also be because patients with diabetes 
are used to monitoring their conditions, in terms of checking blood glucose, monitoring their 
diets, and activity levels [32,33], and the potential benefits of the additional remote 
connections to health care professionals do not add value to their self-monitoring behaviors.   
Despite lack of effects on PROMs, the WSD diabetes cohort showed modest gains in 
glycemic control [21], which was similar to another UK-based RCT [7]. There was also 
evidence that the telehealth trial was effective at reducing hospital admissions and mortality 
[34]. There were no differences on diabetes specific QoL, self-care behaviors, self-efficacy, 
which is consistent with recent pragmatic multicenter RCT in the UK [7], and other long-
term conditions in the WSD trial [8,35].  However, these results demonstrated no substantial 
decreases in these outcomes either. To gain improvement in PROMS, the telehealth system 
may need to be broader than self-monitoring of blood glucose and designed to target the 
behavioral antecedents to these PROMs in individuals with impaired mood and HRQoL. 
Telehealth services may need to be more tailored to the individual, so that there is a match 
between the person and the technology to increase its impact. 
This study also examined the use of novel social functioning with diabetes scales of social 
marginalization and social conspicuousness. Overall, the results showed that there are only 
small impacts in these 2 areas of social life and that they are not impacted upon by telehealth 
as delivered in this study. However, it may be the case that non–home-based remote 
monitoring, other technology-enabled care systems or mobile monitoring [3-6] would have a 
greater impact in these areas.  
Strengths and Limitations  
This clustered RCT addresses many of the methodological limitations identified in previous 
studies and adds evidence to an important gap in the literature.  However, caution is required 
as although this was a relatively large sample of patients with diabetes compared with past 
studies, in the available cases analyses, the sample size did fall short of the recommended 
number required to detect a small effect. Despite recruiting 455 patients at baseline, the 
required number was not met due to attribution. This highlighted the difficulties in recruiting 
and maintaining participants in a trial of this size and complexity; nevertheless, a larger 
sample may help narrow the CIs of effect sizes and identify further statistically significant 
effects. 
Also, the WSD trial was a pragmatic trial, but with associated limitations. While it has good 
ecologic validity, 1 potential criticism is the number of confounding factors (eg, the nature of 
the telehealth intervention delivered at each of the regional WSD sites/participating). Like 
other studies in this area, there is a high risk of selection bias given that the numbers of 
eligible patients the study sample were drawn from is unknown. Nevertheless, the WSD trial 
recruited a large number of patients with diabetes, is 1 of very few UK-based studies 
conducted in the National Health Service, and benefits from high generalizability across 
different centers, given the inclusion of a many general practices (n=204) delivering 
telehealth or standard care to patients with diabetes. However, in his study we did not 
examine differences between patients using insulin as well as oral medication and those who 
were only using oral medication. It is likely that insulin use will have a greater effect on 
HRQoL than medications alone, and thus insulin users may have a greater potential for the 
support via telehealth. This potential impact requires further investigation, especially in 
relation to the timeframes within which telehealth may have positive impacts upon HRQoL 
and psychological distress in each group of patients with diabetes.  
Importantly, as an RCT, this study did not aim to specifically examine the mechanisms by 
which telehealth may impact PROMs. The differences in the types of telehealth and how they 
may differentially affect outcomes needs better investigation – as they likely use different 
mechanisms for action on HRQoL and psychological distress, making it problematic to 
compare the effectiveness of trials. Telehealth solutions also need to be described in 
sufficient detail, to determine how their use in the complex health care environment of 
diabetes management, may lead to improved HRQoL outcomes. Monitoring and interpreting 
readings in diabetes self-management is only 1 domain of a complex set of behaviors patients 
are advised to follow. Thus, the complexity of interventions, including the integrated role of 
telehealth across services, need to be adequately described with the mediating and 
moderating variables also examined. Furthermore, additional types of technology that 
patients with diabetes may use in addition to the telehealth services provided by the general 
practitioner/local authority also need to be considered, as they may mask effects specific to 
these services.   
Implications and Future Research  
The findings have implications for mainstreaming telehealth. Providing telehealth alone, in 
the absence of monitoring and enhancing the mediating mechanisms (eg, self-care behaviors, 
self-efficacy [Cartwright et al. Unpublished data], acceptability [20], and reducing dropout 
[37]) will not necessarily lead to improvements in HRQoL. In the future, further 
improvements to these complex interventions maybe required for telehealth to be used as a 
tool to improve patients’ self-care and HRQoL. For example, evidence-based self-
management interventions could be delivered via telehealth to facilitate the management of 
long-term conditions, such as diabetes and the capability of mobile monitoring may need to 
be integrated into home-based telehealth packages.  
Conclusions  
This study found no substantial impacts of telehealth on either generic or disease-specific 
HRQoL measures in a population with diabetes. However, this study also demonstrated that 
there were no substantial decreases in HRQoL with the introduction of telehealth. Coupled 
with moderate improvements in glycemic control, there is potential promise for telehealth 
interventions, but more effective telehealth interventions aimed specifically at improving 
outcomes measured by PROMs are needed. Self-monitoring using telehealth is insufficient to 
improve PROMS by itself, but we recommend using evidenced based self-management 
techniques targeting self-care and QoL delivered via telehealth, as a tool to facilitate the 
delivery of the intervention.  
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